

10. A host cell comprising a nucleic acid molecule encoding the fusion protein of any one of claims 1 to 8.
11. A method of producing the fusion protein of any one of claims 1 to 8, comprising:
- 5 (1) culturing a host cell comprising a nucleic acid molecule encoding the fusion protein of any one of claims 1 to 9, under a condition that the fusion protein is produced; and
- (2) recovering the fusion protein produced by the host cell.
12. A pharmaceutical composition comprising the fusion protein of any one of claims 1 to 8 and a pharmaceutically acceptable carrier.
- 10 13. A pharmaceutical composition comprising a nucleic acid molecule encoding the fusion protein of any one of claims 1 to 8 and a pharmaceutically acceptable carrier.
14. A use of the fusion protein of any one of claims 1 to 8 in the manufacture of a medicament, wherein the medicament is used for treating or preventing an angiogenic-type disorder characterized by neovascularization, vascular permeability,
- 15 edema or inflammation.
15. A use of the fusion protein of any one of claims 1 to 8 in the manufacture of a medicament, wherein the medicament is used for treating or preventing a clinical condition selected from the group consisting of choroidal neovascularization (CNV), wet age-related macular degeneration (AMD) and geographic atrophy.